# Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)

> **NCT03158805** · PHASE2 · COMPLETED · sponsor: **Lindner Center of HOPE** · enrollment: 60 (actual)

## Conditions studied

- Bipolar Disorder
- Obesity

## Interventions

- **DRUG:** LIRAGLUTIDE
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT03158805
- **Lead sponsor:** Lindner Center of HOPE
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-04-26
- **Primary completion:** 2022-10-11
- **Final completion:** 2023-01-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03158805

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03158805, "Saxenda® in Obese or Overweight Patients With Stable Bipolar Disorder (Investigator Initiated)". Retrieved via AI Analytics 2026-05-23 from https://api.ai-analytics.org/clinical/NCT03158805. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*